The world needs better pain treatments
Pain is widely considered the biggest problem in medicine today: a 2011 market research report indicates that more than 1.5 billion people worldwide suffer from chronic pain,1 more than 21% of who suffer for more than 20 years.2 Adequate treatment is often unavailable or hard to access, and as a specialist business focused on this market niche, we’re determined to tackle this problem.
1 Global Industry Analysts, Inc. (2011) Global Pain Management Market to Reach US$60 Billion by 2015, According to a New Report by Global Industry Analysts, Inc. [Online] Available from: http://www.prweb.com/pdfdownload/8052240.pdf [Accessed 14 April 2018].
2 Langley P.C.: The prevalence, correlates and treatment of pain in the European Union. CMRO. 2011;463-480
“Imagine going through your daily life where everything that you touch, or that touches you, where most every noise around you from a passing car to children playing, causes you pain. We will leave no stone unturned to help these patients.”
Our purpose is to change lives for the better. We believe that change is possible. We invest heavily in innovation, exploring new possibilities to develop smart solutions. Success comes from pioneering treatments that transform patients’ lives for the better. This measure of success drives everything we do.
By 2022, we will be a €2bn entrepreneurial, science-based company, specializing in pain, gout and beyond and deliver five new medicines to patients with diseases with high unmet needs. We are turbo-charging our delivery from our own research and collaborating with external partners.
Our strategy: leading with innovation
We focus our R&D activities on pain and have built up our portfolio with projects “Beyond Pain” and medical devices. This diversifies our risks and opens new markets for us.
“As a worldwide leader in pain management, we are looking for strategic partnerships in research and development to bring innovative solutions to patients with indications with high unmet medical needs. Innovation is at our core and as a fully integrated pharmaceutical company, we can offer support along the whole value chain – from drug development to commercialisation.”
Get to know us
Grünenthal by the numbers
We are an independent, family-owned company with headquarters in Aachen, Germany. We are present in 30 countries with affiliates in Europe, Latin America and the USA.
A mix of strong entrepreneurial spirit, close collaboration and outstanding performance define our approach alongside a commitment to diversity and inclusivity.
Innovation is at the heart of everything that we do. It’s the driving force behind new ideas and future therapies.
Imaginative researcher? Unconventional strategist? Forward-thinking go-getter? We would love to hear from you.
Open Innovation: collaboration at the core
We can’t do everything alone, and we have found some excellent partners to share the load. We believe that open collaborations bring together all the expertise that is relevant to develop innovative medicines for patients.
We are on a strong and solid economic growth path. In the last years, we’ve already made great progress in acquiring external assets and companies. We will continue on this path as it allows us to broaden our portfolio and entrepreneurial basis.
Madrid, Spain, 12 June 2019 – A pan-European survey initiated by Grünenthal and presented at this year’s annual European Congress of Rheumatology (EULAR 2019) in Madrid indicates that gout is being diagnosed late and is not controlled effectively or monitored regularly enough. Despite these significant gaps in the management of the disease, 8 out of 10 patients claim they are satisfied with their current treatment1.
Aachen, Germany, 8 May 2019 – Grünenthal intends to realign its research and development activities. Today, the Corporate Executive Board informed the workforce about the background of the intended changes.
Brussels/Aachen, 2 May 2019 – The European Pain Federation EFIC® and the pharmaceutical company Grünenthal have announced the five research projects that will receive funding as part of the EFIC-Grünenthal Grant (E-G-G). With a total value of €200,000, this biennial grant supports young scientists in their quest to turn creative ideas into research projects that deliver life-changing pain management approaches.
Aachen, Germany, 22 January 2019– Grünenthal announced today that Fabian Raschke has been appointed Chief Financial Officer (CFO) and Member of the Corporate Executive Board. He will assume leadership of Grünenthal’s Finance and IT organisation on 1 February 2019. Fabian currently leads Grünenthal’s Group Controlling and manages over 150 employees, including Finance staff in the affiliates.